PepsiCo, Inc. (NASDAQ:PEP) is making bold operational shifts across its global portfolio as it navigates shifting demand ...

Guidance was raised from $7.60–$7.90 EPS to $7.75–$8, now inclusive of tariffs. Margin expansion guidance increased from "upside to the midpoint" to a specified "150 to 200 basis points" for the year.

A trial testing a nerve-sparing (NeuroSAFE) technique in radical prostatectomy may improve patient-reported outcomes.

Breastfeeding did not appear to be associated with a higher risk of developing locoregional recurrences or contralateral breast cancers,” researchers wrote.

Background Restarting direct oral anticoagulants (DOACs) after a serious bleeding event in patients with atrial fibrillation ...

Q4 2025 Earnings Call Transcript July 15, 2025 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.13. Operator: Good morning, and welcome to the ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday.

Rivian is making significant progress towards profitability due to major cost reductions, despite current sales challenges in ...

Some anime characters are just too strong, as proven by overrated powers from One Punch Man's Saitama, Death Note's Light ...

15-year-old Nolan Grove testified in his homicide trial, claiming the shooting of 12-year-old Kain Heiland was accidental. Surveillance footage tracked the boys' movements leading up to the ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...